Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

$95 million for Marketing Medical Drugs

Through a Qui Tam case involving a company named Boehringer Ingelheim Pharmaceuticals Inc., whistleblower Robert Heiden, a former sales representative for Boehringer, received over $17 million for bringing up the case.

Boehringer promoted Aggrenox, Atrovent, Combivent and Micardis – medical drugs – and prescribed them for the incorrect treatment and in incorrect doses. Health care professionals would buy the drugs and receive reimbursement for them from government health care programs and, sometimes, receive kickbacks from Boehringer. Kickbacks are against the Anti-Kickbacks Statute and, thus, against the False Claims Act.

The FDA permitted the drug Aggrenox for uses involving the avoidance of secondary strokes. Boehringer prescribed Aggrenox for myocardial infarction and peripheral vascular disease. Doctors are permitted to prescribe drugs for other uses than what the FDA approves, but Boehringer is not allowed to sell them for those specific uses.

Combivent is FDA approved to treat the symptoms of bronchospasm in COPD patients on a bronchodilator, while Boehringer promoted Combivent for use before implementing a bronchodilator in the patient.

Boehringer also sold Micardis to treat diabetic kidney disease while it is approved by the FDA to treat hypertension.

Combivent and Atrovent were sold by Boehringer at dosages that surpassed what is covered by health care programs. In addition, Boehringer claimed that Aggrenox was better than Plavix. Though there is a possibility through research and study that this could be true, Boehringer isn’t allowed to make this claim.

Boehringer entered a Corporate Integrity Agreement with the government to establish steps and reviews of their behavior and to identify illegal acts similar to what cost them $95 million in the long run.

allisonberg

allisonberg

Share the Post:

Related Posts